Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

Phase 3 Active not recruiting 170 enrolled ACADIA Pharmaceuticals Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

12-week, randomized, double-blind, placebo-controlled, parallel-group study of carbetocin nasal spray for the treatment of hyperphagia in Prader-Willi syndrome (PWS)

Timeline

Start: 2023-11-27
Primary completion: 2025-10
Completion: 2025-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Carbetocin	Peptide	3.2 mg	Intranasal

Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

Summary

Timeline

Drugs

Indications